Hyaluronic acid influence on platelet-induced airway smooth muscle cell proliferation

Ann-Charlotte Svensson Holm, Torbjörn Bengtsson, Magnus Grenegård and Eva G Lindström

Linköping University Post Print

N.B.: When citing this work, cite the original article.

Original Publication:
Copyright: Elsevier
http://www.elsevier.com/
Postprint available at: Linköping University Electronic Press
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-75382
Hyaluronic acid influence on platelet-induced airway smooth muscle cell proliferation

Ann-Charlotte B. Svensson Holm¹², Torbjörn Bengtsson³, Magnus Grenegård¹ & Eva G. Lindström¹

¹Division of Drug Research/Pharmacology, Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University, SE-581 85 Linköping, Sweden
²Experimental Pathology, Department of Clinical and Experimental Medicine, Linköping University, SE-581 85 Linköping, Sweden
³Department of Biomedicine, School of Health and Medical Sciences, Örebro University, SE-70182 Örebro, Sweden.

Running title: HA influence on platelet-induced ASMC proliferation

Correspondence and requests for reprints should be addressed to:

Ann-Charlotte Svensson Holm, Experimental Pathology, Department of Clinical and Experimental Medicine, Linköping University, SE-581 85 Linköping, Sweden
Tel: +46-10-1031500
E-mail: ann-charlotte.svensson@liu.se.
Abstract

Hyaluronic acid (HA) is one of the main components of the extracellular matrix (ECM) and is expressed throughout the body including the lung and mostly in areas surrounding proliferating and migrating cells. Furthermore, platelets have been implicated as important players in the airway remodeling process, e.g. due to their ability to induce airway smooth muscle cell (ASMC) proliferation. The aim of the present study was to investigate the role of HA, the HA-binding surface receptor CD44 and focal adhesion kinase (FAK) in platelet-induced ASMC proliferation. Proliferation of ASMC was measured using the MTS-assay, and we found that the CD44 blocking antibody and the HA synthase inhibitor 4-Methylumbelliferone (4-MU) significantly inhibited platelet-induced ASMC proliferation. The interaction between ASMC and platelets was studied by fluorescent staining of F-actin. In addition, the ability of ASMC to synthesise HA was investigated by fluorescent staining using biotinylated HA-binding protein and a streptavidin conjugate. We observed that ASMC produced HA and that a CD44 blocking antibody and 4-MU significantly inhibited platelet binding to the area surrounding the ASMC. Furthermore, the FAK-inhibitor PF 573228 inhibited platelet-induced ASMC proliferation. Co-culture of ASMC and platelets also resulted in increased phosphorylation of FAK as detected by Western blot analysis. In addition, 4-MU significantly inhibited the increased FAK-phosphorylation. In conclusion, our findings demonstrate that ECM has the ability to influence platelet-induced ASMC proliferation. Specifically, we propose that HA produced by ASMC is recognised by platelet CD44. The platelet/HA interaction is followed by FAK activation and increased proliferation of co-cultured ASMC. We also suggest that the mitogenic effect of platelets represents a potential important and novel mechanism that may contribute to airway remodelling.
Keywords: airway smooth muscle; airway remodeling, extracellular matrix, hyaluronic acid, CD44, focal adhesion kinase, platelets
**Introduction**

Platelets have been suggested to play a part in the chronic inflammatory disease asthma where different structural changes, such as increased cell number (goblet cells, fibroblasts and airway smooth muscle cells (ASMC)), cause airway remodeling. Platelets have been shown to interact with different cell types, e.g. by recruiting leucocytes through P-selectin in a murine model of chronic allergic inflammation [1, 2]. We have recently found that platelets have the ability to bind to ASMC and induce a significant proliferation [3]. We have also observed that different platelet preparations, e.g. platelet membranes, significantly stimulate ASMC proliferation [4]. These results suggest that not only soluble factors but that the interaction between platelets and ASMC are of importance for the mitogenic effect of platelets. However, the mechanisms involved are far from understood.

Hyaluronic acid (HA), a glycosaminoglycan, is one of the main components of the extracellular matrix (ECM). HA is composed of repeating units of GlcNAc-β(1-4)-GlcUA-β(1-3) and produced by e.g. smooth muscle cells by three different HA synthases (HAS 1-3) using UDP-GlсUA and UDP-GlсNac as substrates [5, 6]. HA is expressed throughout the body including the lung mostly in areas surrounding proliferating and migrating cells and especially during inflammation and tissue repair [7]. HA is therefore believed to play an important role in both proliferation and migration of cells [8, 9]. HA has recently been shown to bind to different receptors, e.g. CD44, a type 1 transmembrane receptor expressed on the surface of smooth muscle cells and platelets. CD44 exists in many different isoforms that all have HA binding properties [10] and regulate several signaling pathways including Src family kinases, Rho family GTPases, extracellular signal-regulated kinases and mitogen activated protein kinase (MAPK) [11, 12] and thereby mediates both cell adhesion and cell growth [13, 14].
CD44 has a structural role in linking the ECM to the cytoskeleton and thereby regulates cell shape and motility [15-17], i.e. properties resembling those of focal adhesions. Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase expressed in most cell types, such as smooth muscle cells and platelets. FAK is recruited at an early stage to focal adhesions and mediates many downstream responses. FAK is an adaptor for protein-protein interactions, and transmit thereby adhesion and growth factor-dependent signals into the cell [18]. FAK has been shown to regulate many different signaling pathways by affecting phosphoinositide 3-kinase, phospholipase C, Rho GTPases and MAPK [19, 20].

The aim of the present study was to investigate the importance of HA, CD44 and FAK-dependent signaling in the interaction between platelets and ASMC and their role in platelet-induced cell proliferation. Increased knowledge regarding ECM and intracellular signaling pathways involved in the interaction between platelets and ASMC might in the future lead to potential important and novel mechanism that may contribute to airway remodelling.
Materials and methods

Chemicals

The chemicals used were as follows: Dulbecco’s Modified Eagle Medium, non-essential amino acids, sodium pyruvate, penicillin and streptomycin (PEST), foetal bovine serum (FBS) and Trypsin-EDTA (Gibco, Paisley, Scotland); CellTiter 96® Aqueous One solution cell proliferation assay (Promega, Madison, WI, USA); streptavidin Alexa Fluor® 488 conjugate and Alexa Fluor®594-phalloidin (Molecular Probes, Eugene, OR, USA); lysophosphatidylcholine (LPC), platelet-derived growth factor (PDGF) and 4-methylumbelliferone (4-MU) (Sigma Chemical Co., St. Louis, MO, USA); CD44 blocking antibody, Protease Inhibitor Cocktail, EDTA-free (100X) and Halt™ Phosphatase Inhibitor Cocktail, 100X (Thermo Fisher Scientific, Fremont, CA, USA); Biotinylated HA binding protein (Merck, Darmstadt, Germany); Antiphosphotyrosine, clone 4G10 (Millipore, Billerica, MA, USA); goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, Santa Cruz, CA, USA); Vectashield (Vector Laboratories Inc, Burlingame, CA, USA); purified mouse anti-FAK (BD Transduction Laboratories™, San Jose, CA, USA); protein A Sepharose CL-4B (GE Healthcare, Little Chalfont, UK); paraformaldehyde (PFA) (Labkemi, Stockholm, Sweden); mouse IgG1 negative control (AbD Serotec, Oxford, UK); PF 573228 (Tocris, Bristol, UK).

Buffers and media

The following buffers and media were used in the experiments: phosphate-buffered saline pH 7.3 (PBS; 137 mM NaCl, 27 mM KCl, 6.74 mM Na₂HPO₄x2H₂O, 1.47 mM KH₂PO₄ and 0.5% BSA); PBS pH 7.3 (1.2 % BSA); Krebs-Ringer phosphate buffer pH 7.3 (KRG; 120 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO₄, 1.7 mM KH₂PO₄, 8.3 mM Na₂HPO₄, 1 mM CaCl₂ and 10 mM glucose); KRG without CaCl₂; acid citrate/dextrose solution (ACD; 85 mM
C₆H₅Na₃O₇, 71 mM H₃C₆H₅O₇ and 111 mM D-glucose); RIPA buffer (2% Triton X-100, 2% sodium deoxycholate, 0.2% SDS, 316 mM NaCl, 2 mM EGTA, 20 mM Tris-HCl); starvation medium (DMEM, 1mM sodium pyruvate, 1% non-essential amino acids, 100 U/ml penicillin, and 100 µg/ml streptomycin); complete medium (starvation medium with 10% foetal bovine serum).

Cell culture

Human ASMC (Promocell, Heidelberg, Germany) were cultured in complete medium in a humidified atmosphere at 37°C and 5% CO₂. ASMC displayed all the reported characteristics of viable smooth muscle cells in culture when examined by light microscopy [21]. ASMC in passages 9 to 20 were used.

Platelet preparation

Fresh blood from healthy donors was obtained from the blood bank at Linköping University Hospital, Linköping, Sweden and platelets were isolated as previously described [3]. In short, five parts of the blood were mixed with one part of ACD solution and centrifuged for 20 min at 220 x g. The platelet-rich plasma obtained in the upper layer was removed and centrifuged for 20 min at 480 x g. The platelet pellet was gently washed and resuspended in KRG without calcium, and the platelets were counted in a Bürker chamber.

ASMC proliferation

ASMC proliferation was measured as previously described [3]. Briefly ASMC (3000/well) were seeded in 96-well plates. After 24 h the medium was changed to starvation medium and incubated for 24 h. Thereafter, cells were incubated for further 24 h in medium supplemented with 0.1% FBS, in the absence (controls) or presence of platelets (ASMC/platelet ratio of
1/1000) and drugs (0.1-10 µg/ml of the CD44 blocking antibody, 10 µg/ml of the mouse IgG1 negative control antibody, 100-600 µM of the HAS-inhibitor 4-Methylumbelliferone (4-MU) and 0.01-1 µM of the FAK-inhibitor PF 573228). Inhibitors were added to both cell types 20 min prior co-incubation. ASMC density and ASMC/platelet ratio were based on previous studies [3, 4].

ASMC proliferation was analysed using the CellTiter96® Aqueous One Solution Cell Proliferation Assay (MTS-assay). Briefly, after incubation with the stimulus, new medium supplemented with 0.1% FBS was added together with the CellTiter 96® Aqueous One Solution Reagent, and the amounts of viable cells were measured spectrophotometrically at 490 nm using a microplate reader (Spectra MAX 340, Molecular Devices, Sunnyvale, CA) [22]. All drug and solvents used were tested for interference with the assay.

Synthesis of HA and microscopic examination of the ASMC/platelet interaction

The ability of ASMC to synthesise HA was investigated by fluorescent staining using biotinylated HA-binding protein (HBP) and Alexa Fluor® 488 streptavidin conjugate. In addition, the interaction between ASMC and platelets was studied morphologically by fluorescent staining of the F-actin using Alexa Fluor® 594-phalloidin and the nucleus using DAPI conjugated Vectashield followed by fluorescence microscopy. ASMC (10 000/well) were seeded in an 8-well chamber slide (Nunc, Rochester, NY, USA) in complete medium and incubated for 24 h in a humidified atmosphere at 37°C and 5% CO₂ followed by 24 h of serum deprivation. Thereafter, cells were incubated for 2 h in DMEM supplemented with 0.1% FBS, in the absence (controls) or presence of platelets (ASMC/platelet ratio of 1/1000) and drugs (10 µg/ml CD44 blocking antibody, 100-600 µM 4-MU and 1 µM PF 573228). Inhibitors were added to both cell types 20 min prior co-incubation. After 2 h of co-incubation
the cells were treated with 4% paraformaldehyde for 30 min in RT followed by incubation with biotin-conjugated HBP (1:100) for 45 min at 37 °C. Afterwards the cells were incubated with streptavidin-conjugated Alexa 488 (1:250) for 45 min at RT. Thereafter the samples were permeabilised and F-actin stained in a mixture of lysophosphatidylcholine (100µg/ml) and Alexa Fluor®594-phalloidin (8µg/ml) in PBS pH 7.3. The chamber slides were mounted with coverslips using DAPI conjugated Vectashield and placed in the refrigerator prior to fluorescence microscopy analysis (Carl Zeiss, Oberkochen, Germany).

Quantification of the amount HBP/image and F-actin/image was made using Image J v. 1.45 (available as freeware from http://rsbweb.nih.gov/ij/). The degree of platelet in close association to ASMC (no visible space between the ASMC and the platelets) and the degree of platelets bound to the area surrounding the ASMC was quantified by manual counting in the fluorescence microscope by an expert in the method. Platelets on total 6-9 images per treatment (3 independent experiments and 2-3 replicates/experiment) were counted and morphologically evaluated whether they were in close association to the ASMC or bound to the area surrounding the ASMC. All pictures had identical settings to enable equivalent image analysis.

**Western blot of FAK**

ASMC (100 000/well) were seeded in 6-well plates in complete medium and incubated for 24 h in a humidified atmosphere at 37°C and 5% CO₂ followed by 24 h of serum deprivation. Thereafter, cells were incubated for 1 hour in medium supplemented with 0.1% FBS, in the absence (controls) or presence of platelets (ASMC/platelet ratio of 1/1000) and drugs (10 µg/ml CD44 blocking antibody, 600 µM 4-MU and 0.1 and 1 µM PF 573228) or 150 ng/ml PDGF. Inhibitors were added to both cell types 20 min prior co-incubation. The cells (both
ASMC and platelets) were thereafter lysed by incubation in RIPA buffer supplemented with 1X phosphatase and protease inhibitor coctail for 30 min on ice followed by centrifugation at 14 000 g at 4°C for 10 min. The supernatant was incubated with 0.5 µg FAK antibody for 2h at 4°C followed by immunoprecipitation over night at 4°C using protein A sepharose. The protein A sepharose/antibody mix was washed three times, diluted in sample buffer and thereafter heated to 95°C for 5 min. The samples were separated on a NuPAGE® 3-8% Tris-Acetate gel (Invitrogen, Carlsbad, CA, USA) using an Invitrogen Novex® Mini-cell. The proteins were transferred to a PVDF membrane using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, Hercules, CA, USA). The membranes were blocked for 1 h in RT with 5% (w/v) dry milk and 0.1% Tween 20 in PBS pH 7.4 to minimise nonspecific binding. The membranes were thereafter incubated for 1 h at RT with a primary mouse antiphosphotyrosine 4G10 antibody (diluted 1:200 in PBS supplemented with 1% (w/v) BSA, 0.1% (v/v) Tween 20 and 0.02% (w/v) sodium acid) and subsequently incubated with horseradish peroxidase-conjugated goat anti-mouse IgG secondary antibody (diluted 1:2000 in 0.1% (v/v) Tween 20 in PBS) for 1 h. HRP antibody-conjugated proteins were visualised by chemiluminescence using Immobilon™ Western Chemiluminescence HRP substrate (Millipore, Billerica, MA, USA).

Statistical analysis

Results are normalised in relation to unstimulated ASMC and are expressed as mean values (% of control) ± standard error of the mean (S.E.M). One-way ANOVA followed by Dunnet´s multiple comparison tests was used for statistical analysis. A p-value < 0.05 was considered to be significant, as denoted * (p < 0.05), ** (p < 0.01) and *** (p < 0.001). Data were analysed using GraphPad Prism™ (GraphPad Software, San Diego, CA).
Results

The role of HA in platelet-induced ASMC proliferation

We have recently observed that platelets have the capacity to bind to ASMC [3] and that platelet-induced ASMC proliferation in our experimental setup is mainly mediated by membrane bound structures [4] suggesting that a physical interaction between platelets and ASMC is important for the mitogenic effect of platelets. ASMC were therefore stimulated with platelets at an ASMC/platelet ratio of 1/1000 in the presence or absence of a CD44 blocking antibody (0.1-10 μg/ml) and the HAS-inhibitor 4-MU (100-600 µM). Proliferation was measured using the MTS-assay and the ASMC/platelet ratio was chosen based on previous findings [3].

The results indicate that the presence of platelets causes a significant increase in the proliferation of ASMC after 24 h of coincubation (Figure 1 and 2A). Interestingly, our data demonstrated that platelet-induced ASMC proliferation was significantly reduced by 0.1-10 µg/ml of a CD44 blocking antibody (Figure 1) and by 600 µM of 4-MU (Figure 2A). Importantly, none of the drugs (the blocking CD44 antibody; Figure 1 inset, 4-MU; Figure 2A inset) affected basal ASMC proliferation significantly and 10 µg/ml of an IgG1 isotype antibody did not affect platelet-induced ASMC proliferation (151.9 ± 0.72, n=3).

The ability of ASMC to synthesise HA was thereafter investigated by staining HA using biotinylated HA-binding protein and Alexa Fluor® 488 streptavidin conjugate followed by fluorescence microscopy. We found that ASMC synthesise considerable amounts of HA (Figure 2B I, 3 independent experiments and 2-3 replicates/experiment). Incubation with 600 µM of the HAS inhibitor 4-MU significantly inhibited HA production in ASMC (Figure 2B II, 2C). Control experiments conducted to investigate the specificity of biotin-conjugated HA-
Figure 1. Effect of a CD44 blocking antibody on platelet-induced ASMC proliferation. The platelet-mediated increase in ASMC proliferation, measured using the MTS-assay, was significantly inhibited by the CD44 blocking antibody (n = 4-7). The inset shows that the CD44 blocking antibody did not have an effect on basal ASMC proliferation. Data are expressed as means ± SEM and One-way ANOVA followed by Dunnet’s multiple comparison tests was used for statistical analysis in this and for the data in the following figures.
Figure 2A

**ASMC Proliferation (% of control)**

- 0 μM
- 100 μM
- 300 μM
- 600 μM

**Platelet-induced ASMC proliferation (% of control)**

- 0 μM
- 100 μM
- 300 μM
- 600 μM

* denotes a significant difference compared to control.
Figure 2. A: Effect of 4-MU on platelet-induced ASMC proliferation. The platelet-mediated increase in ASMC proliferation, measured using the MTS-assay, was significantly inhibited by 600 µM 4-MU (n = 5-6). The inset shows that 4-MU did not affect basal ASMC proliferation. B: Synthesis of HA. ASMC produce HA (I). In addition, 4-MU inhibits HA produced by ASMC after 2 h of incubation. (II) HA (green), F-actin (red) and the nucleus (blue) is fluorescent stained as described in the Materials and methods section. The images shown are representatives of 3 independent experiments (2-3 replicates/experiment) obtained from different cell passages. C: Quantification of the amount HBP/image using Image J. 600 µM 4-MU significantly inhibits HA synthesis in ASMC.
binding protein and streptavidin-conjugated Alexa 488 revealed no nonspecific binding and ASMC morphology and F-aktin levels was not affected by the drug treatments (data not shown).

*The role of HA and CD44 in the interaction between platelets and ASMC*

As previously presented, we observed that platelets induce a CD44 and HA-dependent ASMC proliferation and that ASMC produce HA. Consequently, we wanted to investigated the role of HA and CD44 in the interaction between platelets and ASMC. This was done by incubating ASMC for 2 h in the absence (controls) or presence of platelets and 10 µg/ml CD44 blocking antibody or 600 µM 4-MU followed by fluorescent staining of HA, the actin cytoskeleton and the nucleus of the ASMC (Figure 3, 3 independent experiments and 3 replicates/experiment). We found that platelets bound to both ASMC and the HA-rich area surrounding the ASMC (Figure 3A II). In addition, 10 µg/ml of the CD44 blocking antibody and 600 µM 4-MU significantly inhibited the ability of platelets to bind to the area surrounding ASMC (Figure 3A III-IV and 3B II).

*The role of FAK in platelet-induced ASMC proliferation*

FAK regulates many different signaling pathways by affecting e.g. G-protein linked receptors and transmembrane receptors for different growth factors [23]. The role of FAK in platelet-induced ASMC proliferation was investigated using the FAK inhibitor PF 573228. We found that platelet-induced ASMC proliferation was significantly inhibited by 0.1 and 1 µM of PF 573228 (Figure 4A). 1 µM of PF 573228 also significantly reduced basal ASMC proliferation (Figure 4A, inset). PF 573228 did not affect the morphology of ASMC or the binding between platelets and ASMC (data not shown).
Figure 3A

I: ASMC

II: ASMC+platelets

III: ASMC+platelets+anti CD44 10 µg/ml

IV: ASMC+platelets+4-MU 600 µM

B

I: Degree of platelets in close proximity to ASMC

II: Degree of platelets bound to the area surrounding the ASMC

Figure 3. Effects of 4-MU and a CD44 blocking antibody on ASMC/platelet interaction. ASMC were incubated in the presence or absence of platelets and 4-MU (600 µM) or anti-CD44 (10 µg/ml). A I: ASMC. A II: Platelets bind to both ASMC and the HA-rich area surrounding the ASMC. In addition, 10 µg/ml of the blocking CD44 antibody and 600 µM 4-MU significantly inhibited the ability of platelets to bind to the area surrounding ASMC (A III-IV and B II). HA (green), F-actin (red) and the nucleus (blue) is fluorescent stained as described in the Materials and methods section. The images shown are representatives of 3 independent experiments (2-3 replicates/experiment) obtained from different cell passages and blood donors. White arrows indicate platelets and ASMC. Quantification of platelets in close proximity of ASMC and platelets bound to the area surrounding the ASMC was made by manual counting and is expressed as percent of control (ASMC+platelets).
Figure 4. Effect of PF 573228 on platelet-induced ASMC proliferation. Platelet-induced ASMC proliferation was significantly inhibited by 0.1 and 1 µM of PF 573228 (A, n = 3-5), measured using the MTS-assay. The inset shows that 1 µM PF 573228 also reduced basal ASMC proliferation.
Phosphorylation of immunoprecipitated FAK after 1h of coincubation between platelets and ASMC (ASMC/platelet ratio of 1/1000) in the presence or absence of 0.1 and 1 µM PF 53228 was detected using Western blot analyses. We found that phosphorylated FAK was significantly increased upon coincubation of ASMC with platelets (195.5 ± 27.4, n=4, p < 0.05). We also found a significant reduction of FAK phosphorylation (generated after coincubation between platelets and ASMC) when ASMC and platelets were treated with 1 µM of the FAK inhibitor in PF 573228 (119.5 ± 15.4, n=3, p < 0.05). PDGF (150 ng/ml), used as a positive control, also induced FAK phosphorylation in ASMC, which was reduced by 1 µM PF 573228 (data not shown).

It has previously been shown that FAK is phosphorylated and thereby activated as a consequence of interaction between ECM and surface receptors such as integrins [24]. We were therefore interested in studying whether the CD44 blocking antibody and the HAS-inhibitor 4-MU affected the platelet-induced FAK phosphorylation in ASMC. We found that 600 µM 4-MU significantly inhibited FAK phosphorylation generated after 1h of coincubation between platelets and ASMC, while the CD44 blocking antibody did not have any significant effect (Figure 5).
Figure 5

**Figure 5.** Effect of a CD44 blocking antibody and 4-MU on FAK phosphorylation. Western blot analyses showed that 4-MU significantly inhibited the FAK phosphorylation generated after co-incubation of ASMC and platelets. Expression of phospho FAK was analysed using a primary mouse antiphosphotyrosine 4G10 antibody followed by a secondary horseradish peroxidase conjugated goat anti-mouse IgG antibody. Prior to Western blotting, the amount of DNA in each sample of ASMC was determined. The blot is representative of 4 independent experiments obtained from different cell passages and blood donors. Data obtained from the quantitative analyses of the phospho FAK bands were normalised to ASMC, set to 100% and are expressed as means ± SEM.
**Discussion**

Platelets contribute to airway inflammation and facilitate structural changes, such as increased cell proliferation, observed during the remodeling process [25, 26]. We have previously found that platelets as well as platelet-derived membrane preparations stimulate ASMC proliferation measured using the MTS-assay, thymidine incorporation, measurement of DNA content and manual cell counting [3, 4]. This implies that a close association between platelets and ASMC is essential for the increased proliferative activity. However, the role played by specific surface receptors and their corresponding ligands and intracellular signaling pathways are unknown. The present study elucidated the possible role of HA (one of the main ECM component), the HA-binding receptor CD44 and FAK in platelet-induced proliferation of ASMC.

It has previously been shown that platelets bind to HA via surface expressed CD44 [27]. In our study, it was found that a CD44 blocking antibody significantly inhibited the ability of platelets to bind to the HA-rich area surrounding the ASMC. Furthermore, the HAS-inhibitor 4-MU (which reduced HA-synthesis) also decreased the amount of platelets adhering to the surface between the ASMC. The HAS-inhibitor as well as the CD44 blocking antibody significantly inhibited the mitogenic effect of platelets in co-cultures with platelets and ASMC, without affecting ASMC proliferation in the absence of platelets. Interestingly, the drugs used did not inhibit direct interaction between platelets and ASMC.
Taken together, we suggest that CD44 mediates platelet/HA binding, and that this represent one of the crucial events for the increased proliferation of co-cultured ASMC. Our results also indicate that part of the pro-proliferative effect of platelets is due to CD44-independent interactions with the ASMC. Furthermore, it has been shown that T-lymphocytes increase DNA synthesis in ASMC through a mechanism involving CD44 [28]. HA has a molecular mass ranging between 1-10 000 kDa and the high molecular weight HA (HMW-HA, 500-10 000 kDa) is produced by HAS 1-3 while low molecular weight HA (1-500 kDa) is produced by enzymatic degradation of HMW-HA by hyaluronidases (HYAL) or through oxidative hydrolysis by reactive oxygen species (ROS) of HMW-HA [29, 30]. Platelets possess HYAL-2 that, in cooperation with CD44, may cleave HA into small pro-proliferative fragments [31-34]. Interestingly, we recently found that the platelet/ASMC interaction results in increased ROS-production [3]. Consequently, it is tempting to speculate that platelets facilitate degradation of HA into smaller pro-proliferative fragments. However, the exact link between platelet/HA interaction and the subsequent increase in ASMC proliferation remains to be determined.

Previous studies have indicated that the HA-binding receptor CD44 possess properties resembling those of focal adhesion molecules, e.g. participation in the regulation of cell morphology and motility [15-17]. Furthermore, it has been shown that FAK is phosphorylated and thereby activated as a consequence of interaction between ECM and surface receptors such as integrins, and thereby influence proliferation and cell migration [24]. In the present study, we found that the platelet-induced ASMC proliferation was significantly inhibited by the competitive FAK inhibitor PF 573228. In accordance, it has been reported that antisense oligonucleotides directed against FAK inhibited proliferation of pulmonary artery smooth muscle cells and glioma cells [35, 36]. In the present study, morphological analyses revealed
that PF 573228 had no effect on the interaction between platelets and ASMC. This suggests that PF 573228 suppress platelet-induced ASMC proliferation without reducing the binding of platelets to HA and ASMC.

We also found that the HAS inhibitor 4-MU, but not the blocking CD44 antibody, significantly inhibited FAK phosphorylation (detected using Western blot analyses) generated after coincubation between platelets and ASMC. This indicates that platelet binding to HA is an initial and important step that ultimately results in FAK-activation. It has previously been suggested that HA is able to induce FAK phosphorylation [20, 37], FAK-dependent activation of MAPK and secretion of the inflammatory mediator metalloproteinase-2 [20, 37]. Taken together, we propose that platelet/HA interaction is a prerequisite for subsequent FAK-activation in a co-culture of ASMC and platelets. Furthermore, our results demonstrated that FAK activation generated in a co-culture of ASMC and platelets is associated with increased proliferation of ASMC.

We have previously described that platelets binding to ASMC may be pivotal for the pro-proliferative effect of the former cell type [3, 4]. In light of our novel findings it is possible that platelets bound to the HA-rich area surrounding the ASMC are the main reason for the observed mitogenic effect. However, it should be emphasised that ROS as well as LOX activity may contribute to ASMC proliferation in a co-culture of platelets and ASMC [3, 4]. From a broad perspective, it is therefore obvious that the mitogenic action of platelets is multifactorial. The precise connection between HA, CD44, ROS, FAK and LOX activities in the cross-talk between platelets and ASMC remains to be determined.
In conclusion, our findings demonstrated that ECM has the ability to influence platelet-induced ASMC proliferation. Specifically, we propose that HA produced by ASMC is recognised by platelet CD44. The platelet/HA interaction is followed by FAK activation and increased proliferation of co-cultured ASMC. We also suggest that the mitogenic effect of platelets is partly due to CD44-independent interaction with ASMC. This action of platelets represents a potential important and novel mechanism that may contribute to airway remodeling. The results may also have impact in the development of new pharmacological strategies in the treatment of patients with inflammatory airway disorders.
Acknowledgements

This work was supported by grants from strategic areas Cardiovascular Inflammation Research Centre (CIRC) and Material in Medicine, the Heart- and Lung foundation, the County of Östergötlands Län, STIFUD, Olle E and the Swedish Research Council.

Disclosures

The authors declare that they have no conflict of interest.
References


